GLP-1 waste and packaging draw environmental criticism

Commentators this month have started asking what happens to the millions of single-use injector pens used for weekly GLP-1 shots like Wegovy and Zepbound, and how much energy goes into keeping those injections cold from factory to pharmacy to home refrigerator. The sources reviewed for this story do not contain specific figures on pen waste volume, disposal methods, or the carbon footprint of cold-chain shipping for these drugs, so those numbers are not yet known publicly in the reporting available.

What is documented is a shift already underway in how these drugs are packaged and delivered. Novo Nordisk's oral Wegovy pill won FDA approval in December 2025, and patients began accessing it soon after ^[2]. Eli Lilly's rival oral drug, orforglipron, was expected to reach the US market within months of a January 2026 report ^[2]. Unlike the injectable versions of these drugs, the pills do not need refrigeration. One patient interviewed, a 53-year-old librarian in St. Louis who has used injectable Wegovy since June 2025, said she was drawn to the pill partly because it would make travel easier since it "won't require refrigeration, like injections do" ^[2].

The scale of the underlying market helps explain why packaging and shipping have become a subject of scrutiny. About 1 in 8 US adults said they were taking a GLP-1 drug for weight loss, diabetes, or another condition as of November 2025, according to a KFF poll ^[2]. Analysts at Goldman Sachs projected in August 2025 that oral GLP-1 pills alone could capture roughly 24 percent, or about $22 billion, of the global weight-loss drug market by 2030, with the broader GLP-1 market potentially approaching $100 billion by the 2030s ^[2]. That kind of volume, spread across tens of millions of weekly injector pens plus the refrigerated trucks and storage needed to keep them stable, is the backdrop for the waste concerns commentators have raised, even though this reporting does not include a quantified estimate of that waste.

Why it matters for patients

For patients, the practical difference is mostly about daily logistics rather than the medicine's effect on weight. Injectable GLP-1 drugs require patients to store pens in a refrigerator and dispose of used needles and pens as medical waste. Oral versions remove both requirements, which patients like the St. Louis librarian have cited as a reason to consider switching or starting treatment with a pill ^[2]. Cost may factor in too: Novo Nordisk's Wegovy pill has cash prices ranging from $149 to $299 per month depending on dose, somewhat below the newly lowered $349 monthly cash price for injectable Wegovy and well below the $449 monthly cash price for the highest-dose Zepbound vials ^[2].

However, clinical trial data reviewed shows injectable drugs still produce somewhat greater average weight loss than the pills, based on separate late-stage studies, and some obesity medicine specialists say they expect to continue favoring injections for that reason ^[2]. So any decision about which form to use involves trading off convenience and packaging burden against differences in effectiveness and side-effect discontinuation rates, which ranged from about 7 percent or less for the injections to 10.3 percent for the highest dose of Eli Lilly's oral drug in trial data ^[2].

What happens next

Eli Lilly's orforglipron pill was expected to receive US approval within months of the January 2026 reporting cited here ^[2]. Beyond that, the sources available do not include a timeline for any formal environmental assessment, regulatory review, or industry response specifically addressing injector pen waste or cold-chain shipping emissions, so those developments remain unknown at this time.